Pliant Therapeutics announced that the latest data from the Phase 1 clinical trial of its investigational drug Pln-101095 for patients with immune checkpoint inhibitor (ICI)-refractory solid tumors will be presented in a special report at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

老虎证券2026/04/18 17:43

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Vestas Wind Systems Set for Margin Growth -- Market Talk

Dow Jones•2026/08/27 06:57

"Opportunities Emerge After Historic Crash"! Citi Bets on Oracle (ORCL.US) Shares Doubling, Adds to 90-Day Catalyst Watch List

Recently, Citi added the IT giant to its 90-day positive catalyst watch list. The bank maintains a "buy" rating with a target price of $330.

智通财经•2026/08/27 06:51

TotalEnergies completes transfer of 10% Arctic LNG 2 stake to Novatek unit NordLine

Reuters•2026/08/27 06:50

Sleep Cycle names CTPO Mikael Kågebäck acting CEO, replacing Erik Jivmark

Reuters•2026/08/27 06:49